You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Nvidia customers in the US and the Middle East expect that the newly introduced A100 servers will accelerate research into the novel coronavirus.
Irvine, California-based Fluxergy is working with the MGB Center for COVID Innovation to evaluate the firm's research-use-only COVID-19 testing platform.
RenalytixAI's flagship product is KidneyIntelX, which applies artificial intelligence to patient data to aid in the treatment of progressive kidney disease.
Cowen said that Hologic is on track to more than double its Panther system placements to about 500 this year, driven by SARS-CoV-2 test demand.
The platform combines Leica's laser microdissection tool and PBI's pressure cycling tech to enable better extraction and digestion of proteins from biopsies.
Lexent's technology integrates low-pass whole-genome sequencing, fragmentomics, and DNA methylation to detect early stage disease.
The PCR-based test is based on the US Centers for Disease Control and Prevention's CDC 2019-Novel Coronavirus Real-Time RT-PCR Diagnostic Panel.
With a three-pronged approach, a team led by Mount Sinai researchers examined the functional effects of noncoding de novo mutations on cardiac development.
The test is based on the US Centers for Disease Control and Prevention's SARS-CoV-2 panel and detects two regions of the virus' nucleocapsid gene.
A team of researchers in Germany investigated gene expression in airway cells of SARS-CoV-2 patients, finding increased interaction between epithelial and immune cells.
FBB Biomed, cofounded by a diagnostics industry veteran, is attempting to develop a blood RNA test to predict COVID-19 disease severity.
Investigators reported that methylation profiling could distinguish brain cancer subtypes and could detect kidney cancer with striking sensitivity in early experiments.
Both tests are authorized for use by any laboratory CLIA certified to perform high-complexity tests, according to the FDA.
Both PCR-based tests are designed to detect SARS-CoV-2 nucleic acid in upper respiratory specimens and may only be performed by their developers.
Developers are improving and expanding the software that has been helping match patients to molecularly targeted drugs at the institute for over three years.
The SICILIAN algorithm, which uses statistical modeling to score candidate fusions in single-cell RNA sequencing data, is being used to map splice sites in individual tumor cells.
In one study, the UK-based firm found that its RaDaR assay detected circulating tumor DNA in lung cancer patients up to a year before standard clinical progression occurred in most of the cases.
The firm's SmartChip platform consists of a high-throughput liquid dispenser and a PCR instrument and can provide more than 5,000 reactions in one run.
The startup has exclusively licensed an integration engine from the University of Miami to augment its VIPER platform and improve trial recruitment specifically in precision oncology.
The two PCR-based tests are designed to detect SARS-CoV-2 nucleic acid in respiratory samples including nasopharyngeal swabs and bronchoalveolar lavage specimens.
The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.
NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.
Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.
In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.